证券代码：300841 证券简称：康华生物 公告编号：2025-032 关于实际控制人及其一致行动人部分股份解除质押和质押 的公告 成都康华生物制品股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏,并就其保证承担个别和连带的责任。 成都康华生物制品股份有限公司（以下简称"公司"）于近日接到控股股东、 实际控制人王振滔先生及其一致行动人奥康集团有限公司（以下简称"奥康集团"） 的通知，获悉王振滔先生将其持有的公司部分股份办理了质押业务，奥康集团将 其持有的公司部分股份办理了解除质押和质押业务，具体情况如下： 二、 本次股东股份质押的基本情况 | | 是否为 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 控股股 | | | 占公 | | 是否 | | | | | | 股东 | 东或第 | 本次质押 | 占其所 | 司总 | 是否 | 为补 | 质押起始 | 质押到 | | 质押 | | | 一大股 | 股份数量 | 持 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-031 成都康华生物制品股份有限公司 关于实际控制人及其一致行动人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏,并就其保证承担个别和连带的责任。 三、其他说明 1、本次解除股份质押与公司生产经营相关需求无关。 2、截至本公告披露日，控股股东、实际控制人王振滔先生及一致行动人奥 康集团质押股份数量占其所持公司股份数量比例已经超过 50%但未达到 80%。 王振滔先生未来半年内到期的质押股份累计数量为 1,500,000 股，占其所持股份 的 10.71%，占公司总股本的 1.13%；未来一年内到期（包含前述未来半年内到 期）的质押股份累计数量为 1,500,000 股，占其所持股份的 10.71%，占公司总股 本的 1.13%。奥康集团未来半年内到期的质押股份累计数量为 1,870,000 股，占 其所持股份的 11.47%，占公司总股本的 1.41%；未来一年内到期（包含前述未来 半年内到期）的质押股份累计数量为 1,870,000 股，占其所持股份的 11.47%，占 公 ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Market Overview - The Shanghai Composite Index closed at 3380.45 points, above the five-day moving average, with a gain of 0.38% [1] - The total trading volume of A-shares reached 752.206 billion yuan [1] Stocks Performance - A total of 730 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Fulejia (Code: 301371) with a deviation rate of 8.24% and a daily increase of 12.17% [1] - Huahai Pharmaceutical (Code: 600521) with a deviation rate of 7.56% and a daily increase of 10.00% [1] - Aofei Entertainment (Code: 002292) with a deviation rate of 7.46% and a daily increase of 10.02% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the five-day moving average include: - Fulejia: Latest price 36.05 yuan, five-day moving average 33.31 yuan [1] - Huahai Pharmaceutical: Latest price 15.62 yuan, five-day moving average 14.52 yuan [1] - Aofei Entertainment: Latest price 9.77 yuan, five-day moving average 9.09 yuan [1] - Other notable stocks with high daily turnover rates include: - Huifeng Diamond (Code: 839725) with a daily increase of 9.56% and a turnover rate of 14.77% [1] - Beiningmei (Code: 002570) with a daily increase of 10.07% and a turnover rate of 22.33% [1]

Group 1: Financial Performance and Projections - The company aims to strengthen marketing management and expand production capacity to improve operational performance, targeting a significant return for investors [3] - The annual rabies vaccine exposure population in China is approximately 40 million, with a vaccination rate of only 35%, indicating a substantial growth opportunity in the market [3] - The company anticipates a decline in sales for the first quarter of 2025, but expects improvement in the second quarter and the second half of the year [4] Group 2: Product Development and Market Strategy - The company has signed an exclusive licensing agreement with HilleVax, Inc. for the overseas development of a six-valent norovirus vaccine, with clinical trials yet to commence [3] - The company is focusing on the development of a new diploid cell rabies vaccine, which is expected to meet the increasing demand for safer and more effective vaccines [3] - The company plans to enhance its marketing network and brand building to improve product penetration and sales [5] Group 3: Challenges and Responses - The company has faced significant declines in vaccine sales, attributed to industry conditions and competition, but is actively seeking to regain market share [5] - The production expansion project has been delayed, with the company emphasizing the importance of learning from past experiences to avoid future setbacks [4] - The company is committed to improving its operational strategies, including cost control and marketing tactics, to adapt to market changes [7] Group 4: Investor Relations and Market Confidence - The company has repurchased 3 million shares to enhance shareholder value and is focused on restoring investor confidence through improved financial results [6] - The stock price has been under pressure, prompting the company to engage in market management strategies [7] - The management team is experienced and is implementing changes to adapt to competitive pressures and market demands [5]

证券代码：300841 证券简称：康华生物 公告编号：2025-030 一、股东大会审议通过的权益分派方案情况 1、公司 2024 年年度权益分派方案已获 2025 年 5 月 9 日召开的 2024 年年 度股东大会审议通过，具体内容为：以实施权益分派股权登记日登记的总股本（剔 除回购证券专用账户的股份）为基数，向全体股东每 10 股派发现金红利 10 元 （含税），送红股 0 股（含税），以资本公积金向全体股东每 10 股转增 0 股。 在利润分配预案披露日至实施权益分派股权登记日期间，如出现股权激励行权、 可转债转股、股份回购等情形，公司股本总额发生变动的，则以实施分配方案时 股权登记日的享有利润分配权的股份总额为基数，按照每股现金分红金额不变的 原则对分配总额进行调整。 成都康华生物制品股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，成都康华生物制品股份有限公司（以下简称"公司" 或"本公司"）总股本为 132,946,899 股，公司回购专用证券账户中股份数量为 3,00 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-029 成都康华生物制品股份有限公司 关于注销回购股份并减少注册资本通知债权人的公告 二、通知债权人内容 针对公司本次注销回购股份并相应减少注册资本事项，根据《中华人民共和 国公司法》《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相 关法律、法规的规定，公司特此通知债权人，债权人自本公告之日起四十五日内， 有权凭有效债权文件及相关凭证要求公司清偿债务或者提供相应担保。债权人未 在规定期限内行使上述权利的，不会因此影响其债权的有效性，相关债务（义务） 将由公司根据原债权文件的约定继续履行。 债权人可采用现场、邮寄或电子邮件的方式申报，具体如下： 1、申报时间： 2025年5月12日起45日内（工作日的9:00-11:30、13:30-16:30） 2、申报地点和申报材料送达地点： 四川省成都市龙泉驿区北京路182号 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有 虚假记载、误导性陈述或重大遗漏。 一、公司注销部分回购股份减少注册资本的情况 成都康华生物制品股份有限公司（以下简称"公司"） 于2025年4月17日召开 的第 ...

Investment Rating - The report does not explicitly state an investment rating for the vaccine industry Core Insights - The overall trend in the vaccine industry shows a decline in batch approvals for most vaccine types in Q1 2025, with some exceptions showing recovery or growth in demand [7][29][46] Summary by Category Multi-Component Vaccines - In Q1 2025, multi-component vaccines saw a total of 17 batch approvals, a decrease of 26% compared to the previous year [11][15] - The five-component vaccine maintained its batch approval at 17, while the four-component vaccine had no approvals [15][12] Pneumonia Vaccines - Total batch approvals for pneumonia vaccines in Q1 2025 were 23, down 30% year-on-year [19][21] - The 13-valent pneumonia vaccine had 19 approvals, remaining stable, while the 23-valent vaccine saw a significant drop to 4 approvals, down 71% [24][19] HPV Vaccines - HPV vaccine approvals increased to 57 batches in Q1 2025, a growth of 63% [29][27] - The two-valent HPV vaccine saw a remarkable increase of 367%, with all approvals coming from Wantai Biological Pharmacy [29][32] Influenza Vaccines - Influenza vaccine approvals totaled 29 batches, a significant increase of 263% year-on-year [34][38] - The three-valent influenza vaccine had 28 approvals, while the four-valent vaccine had only 1 approval, down 67% [38][41] Rabies Vaccines - Batch approvals for rabies vaccines increased to 223 in Q1 2025, a growth of 37% [46][48] - The freeze-dried rabies vaccine accounted for the majority of approvals, with Chengda Biological achieving 105 approvals, a 110% increase [48][46] Varicella Vaccines - Varicella vaccine approvals slightly decreased to 83 batches, down 2% [53][54] - The largest contributor was Baike Biological, with 33 approvals, marking a 38% increase [54][53] Hib Vaccines - Hib vaccine approvals fell to 7 batches, a decrease of 50% [59][58] EV71 Vaccines - EV71 vaccine approvals continued to decline, with only 4 batches approved, down 69% [64][63] Rotavirus Vaccines - Rotavirus vaccine approvals totaled 21 batches, a decrease of 46% [68][67] DTP Vaccines - DTP vaccine approvals increased to 18 batches, a growth of 167% [72][73] Meningitis Vaccines - Meningitis vaccine approvals totaled 85 batches, down 34% [78][79] - The AC polysaccharide vaccine accounted for 55 approvals, a decrease of 47% [84][79] Hepatitis B Vaccines - Hepatitis B vaccine approvals increased to 87 batches, a growth of 28% [91][90] IPV Vaccines - IPV vaccine approvals totaled 22 batches, a decrease of 33% [93][92]

北京中伦（成都）律师事务所 关于成都康华生物制品股份有限公司 2024 年年度股东大会的 法律意见书 致：成都康华生物制品股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律、法规及规范性文件的规定，北京中伦（成都）律师事务 所（以下简称"中伦"或"本所"）指派律师出席了成都康华生物制品股份有限 公司（以下简称"公司"）2024 年年度股东大会（以下简称"本次股东大会"）， 对本次股东大会的合法性进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 - 1 - 法律意见书 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承 ...

证券代码：300841 证券简称：康华生物 公告编号：2025-028 成都康华生物制品股份有限公司 （问题征集专题页面二维码） 特此公告。 成都康华生物制品股份有限公司 董事会 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）《2024年年度报告》 及其摘要已于2025年4月19日在中国证券监督管理委员会指定的创业板信息披露 网站巨潮资讯网（http://www.cninfo.com.cn）上披露。为使投资者进一步了解公司 2024年年度经营情况，公司定于2025年5月14日（星期三）下午15:30-17:00在全景 网举办2024年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业 绩说明会。 2025 年 5 月 9 日 出席本次说明会的人员有：公司董事长王振滔先生，董事、总裁吴红波先生， 董事、副总裁兼财务负责人、董事会秘书吴文年先生，独立董事方小波先生（如 有特殊情况，参与人员可能进行调整）。 为充分尊 ...